Cold-adapted (ca) mutants of influenza A viruses have been adapted to grow in eggs or primary chicken kidney cell cultures at 25°C, a temperature restrictive for the growth of wild-type viruses (6, 7) . Such a mutant of the H2N2 strain A/Ann Arbor/6/60 (A/AA/6/60-ca) has been proposed for use as a master strain in the development of living attenuated vaccines against influenza A (2) . Recombinants of this strain and several virulent influenza A viruses have been used in a number of clinical trials and shown to be attenuated and immunogenic when administered to animals and humans (9) .
We recently described a sensitive clearance test for determining the immunogenicity of influenza viruses (18) . The test is based on the intranasal vaccinating dose required to induce inhibition of multiplication of unadapted influenza viruses in the lungs of mice. Considerable differences in immunogenicity were demonstrated between two H3N2 influenza viruses and an HlNl virus after each had been cloned in cell culture at 39°C. In this study, the same model was used to determine the immunogenicity of a number of recombinants of A/AA/6/60-ca in comparison with their parental strains. The capacity of these recombinants to induce heterologous cross-protection between influenza types and subtypes is also examined.
MATERIALS AND METHODS
Viruses. Table 1 summarizes the origin and gene composition of A/AA/6/60-ca and the various ca recombinants (determined by RNA analysis [1] ) used in the present study. Wild-type viruses that were used to prepare each recombinant are also included. Each recombinant was obtained by coinfection of primary kidney cells with a wild-type virus and the cold-adapted master strain A/AA/6/60-ca, whose derivation from the wild-type A/AA/6/60 has been described previously (6) . All ca recombinants, the parental A/AA/6/60-ca, and the wild-type parental strains were obtained from H. F. Maassab Except where mentioned, all viruses were grown in fertile chicken eggs for 2 days at 33 to 34°C, and the resulting stocks were put into ampoules for storage at -70°C.
Mice. Male mice have been shown in other studies to allow more rapid rates of multiplication of influenza A than female mice (M. F. Warburton, Ph. D. thesis, Australian National University, Canberra, 1963) and were used throughout. CSL white mice, randomly bred in a closed colony (16) , were used, and mean weights per animal after 3, 4, 5, and 6 to 7 weeks of growth were 9, 15, 20, and 25 g, respectively. At the time of inoculation each mouse was an anesthetized by intraperitoneal inoculation with 0.2 ml of 3.33% (wt/vol) 2,2,2-tribromoethanol in 3.33% (vol/vol) tertiary amyl alcohol. Virus inocula were instilled intranasally in each mouse in a total volume of 0.05 ml, using a calibrated 0.025-ml dropping pipette. Control mice received the same volume of phosphate-buffered saline (PBS). All animals were housed at a constant temperature of 21 to 22°C in groups of not less than six. None of the viruses used in this study produced respiratory symptoms or consolidation with an increase in lung weight.
Preparation of lung and turbinate extracts. Mice were killed by increasing the anesthetizing dose 2.5 times. Lungs and/or turbinates from each mouse were removed aseptically, placed into tared bottles containing 1.0 ml of PBS with gelatin (2.5 mg ml-1), penicillin (1,000 U ml-'), streptomycin (1,000 ,ug ml-1), gentamycin (50 ,ug ml-1), and fungizone (1 ,ug ml-1), and their weights were determined. Extracts of each organ were prepared by grinding in a chilled glass homogenizer in the presence of alumina to produce a suspension of approximately 15% (wt/vol) for lungs for 5% for turbinates. Each suspension was centrifuged at 60 x g for 10 min, and the supernatant was removed and stored for assay at -700C.
Virus assays. All extract titrations were carried out in confluent 2-day cultures of the MDCK cell line prepared in For plaque assays, duplicate MDCK monolayer cultures in six-well plates were washed with PBS and inoculated with 100-,lI dilutions of each isolate. After adsorption for 45 min at 20°C, 3 ml of an overlay medium warmed at 45°C was applied. The medium consisted of Leibovitz L-15 medium with glutamine (0.15 mg ml-'), HEPES buffer (0.01 M; pH 6.8), trypsin (1 pug ml-'), agarose (0.9%), and antibiotics.
After the overlay had hardened, each plate was incubated for 5 days in a 5% CO2 atmosphere at 34°C. Plaques were counted without the addition of a stain.
Serology. Hemagglutinin inhibition (HI) antibody titrations of mouse sera were carried out with 4 hemagglutinating units of antigen and 0.05% chicken erythrocytes (14 Immunogenic response of mice to a single intranasal dose of ca and parental wild-type viruses described in Table 1 . Groups of mice were inoculated with various doses of each ca and parental wild-type virus. After 4 weeks each mouse was challenged with 104i5 TCID5o of wild-type virus with similar surface antigens to the vaccine virus and killed after a further 3 days. Lung extracts were prepared from each animal, and the virus present was determined. The mean + SEM for five to six animals per group is shown. Open histograms represent yields from mice inoculated with ca viruses, and shaded histograms represent yields from mice inoculated with wild-type viruses. The results in Fig. 1 Extent of growth of ca recombinants and wild-type parental viruses in the respiratory tracts of mice. Differences in immunogenicity between ca viruses and their wild-type parent strains in Fig. 1 were considered likely to be due to the restricted growth of ca viruses in the respiratory tracts of CSL mice (12) . Restriction has been previously demonstrated for AIAAI6/60-ca in comparison with a contemporary virulent H2N2 strain (19) . The ca viruses used in the present study were also examined for evidence of growth restriction.
Doses of 1045 TCID50 of each ca virus and its wild-type parental strain were inoculated by the intranasal route into groups of six mice. After 3 and 4 days, individual mice were sacrificed, and extracts of both lungs and turbinates were 8 7 prepared for virus assay. The results in Fig. 2 Fig. 4 . In the first experiment (Fig. 4, panel A) , a 3.7 to 4.5 log1o TCID5( reduction in titer in the lung was noted for both the homologous A/AA/6160 and the heterologous AIQldI6/72, A/Vic/3/75, and A/NT/60/68 influenza A challenge viruses (Student's t test; P < 0.01 for A/NT/60/68; P < 0.001 for the others). For B/Singapore/222/79 a reduction of 1.2 log10 TCID50 was noted, which was marginally significant (P < 0.06). Because egg-derived antigens in both the vaccine and the challenge viruses could have contributed to heterologous cross-protection, a further experiment was carried out in which mice were inoculated with two doses of 105 TCID50 of egg-grown AIAA/6/60-ca and challenged with the HlNl virus A/HK/123/77 or B/Singapore/222/79 after growth in either eggs or MDCK cell cultures (Fig. 4, panel B) . Although protection was noted against the HlNl viruses grown in either host, the observed reduction in titer for B/Singapore/222/79 when grown in either host was not significant. To further clarify the situation for B/Singapore/222/79, the virus titers of parallel lung extract samples from mice challenged with B/Singapore/222/79 in the second experiment were determined by more accurate plaque assays. The mean titer + SEM for the egg-grown challenge was 5.01 ± 0.35 log1,) PFU per lung for the control and 4.30 0.39 for the vaccinated group; for the MDCK challenge these figures are 3.44 ± 0.31 and 3.11 ± 0.09. Neither of these differences was significant (P < 0.1).
Relationships between the hemagglutinin surface antigens of various influenza strains used in the cross-protection experiments were examined by cross-HI tests (Table 3) . Substantial differences are apparent, indicating that common determinants, undetectable by HI tests, are responsible for the clearance of influenza A challenge strains of different subtype in Fig. 4 . In the first (A), both vaccine and challenge viruses were grown in chicken embryos. In the second (B), certain challenge viruses were grown in MDCK cell cultures. Student's t test; P < 0.001 (***); P < 0.01 (**); 0.05 < P < 0.1 (±).
DISCUSSION
In this study the immunogenicity of several ca and wildtype influenza A viruses was determined from the intranasal dose that was sufficient to prevent multiplication of a wildtype challenge in the respiratory tracts of CSL mice. The acquisition of ca lesions by several H2N2, H3N2, and HlNl wild-type viruses greatly reduced their immunogenicity (Fig.  1 ). This reduction is probably related to the decreased capacity of ca viruses to multiply in the respiratory tract (Fig. 2) , which has also been observed with inbred CBA/H mice (12) , ferrets (7) , hanWters (17) , and newborn rats (8 (Fig. 3) , and such a relationship is apparent between wild-type'viruses with similar surface antigens (Fig. 1) . In humans influenzal illness caused by HlNl viruses has been shown to be relatively mild and the virus isolation rate much lower than that produced by H3N2 viruses (21) . A ca recombinant vaccine with HlNl surface antigens also produced a lowered rate of seroconversion and induced virus shedding in slightly fewer volunteers than a ca recombinant H3N2 vaccine (20) . The (10) . A suggested reason for this virulence is the presence of a wild-type parental gene coding for nonstructural protein in this recombinant (10) ( Table 1 ). The present studies do not reveal any immunogenic property of CR-18 that might be responsible for residual virulence, which could be a property of all ca recombinants when administered at these doses. If our findings apply to humans, two relatively small doses administered at intervals of 3 to 4 weeks should overcome any problem of residual virulence and produce substantial immunity. The cost of the vaccine would be much less than that of a single, very high dose.
Studies are at present under way to determine the effects of vaccination with ca viruses in mice primed with virulent heterotypic viruses in an attempt to mimic the situation in adult humans at times of major antigenic shift.
